Cognitive & MoodGrade B
Selank
A tuftsin-derived anxiolytic heptapeptide reported to reduce anxiety without sedation or dependence.
- Regulatory status
- Approved in Russia; not FDA approved
- Half-life
- Minutes (effects persist ~20h)
- Route
- Intranasal or subcutaneous
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Modulates GABA-ergic and serotonergic transmission and raises BDNF expression.
Studied and reported uses
- Anxiety
- Stress resilience
- Cognitive clarity
Dosing information
Reported range250–500 mcg daily intranasally
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Nasal irritation
- Fatigue
- Mild blood pressure changes
Research evidence
GAD comparison
Comparable anxiolysis to benzodiazepines in small trials.